TokenPost topic
1 TokenPost story is tagged LXEO. The newest appear first.
The target changes followed interim data from a Phase I/II trial of LX2020 for PKP2 arrhythmogenic cardiomyopathy. Raymond James views Lexeo as a strong buy.
Nov 16, 2026, 2:13 PM EST ยท Insights & Views